Preliminary Report on the Safety and Tolerability of Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a disease-modifying therapy for Parkinson’s disease: Phase IIa double-blind, randomized controlled trial
Objective: To select the safest and most effective number of repeat doses of allogeneic mesenchymal stem cells (MSC) purified from bone marrow-derived from a healthy…Conventional anti-epileptic drugs used in North Sea Progressive Myoclonus Epilepsy revisited in a Drosophila model
Objective: To determine the effect of conventional anti-epileptic drugs in a North Sea Progressive Myoclonus Epilepsy (NS-PME) Drosophila model. Background: In 2011, Corbett et al.…Recruiting people at risk of Parkinson’s disease: comparative data from PPMI Online and HeBA Kassel
Objective: To compare a US- and Germany-based staged screening process to identify people at risk of developing Parkinson’s disease (PD). Background: The Parkinson’s Progression Marker…The Dystonic Drive – A Systematic Review on Coherence Analysis in Dystonia
Objective: To perform a systematic review on coherence analysis in dystonia. We focus on different modalities and describe the relation of abnormal coherent frequency bands…The effect of peptic ulcer disease on Parkinson’s disease
Objective: To compare patients with Parkinson’s disease (PD, PwP) with and without peptic ulcer disease (PUD) regarding cognition, psychiatric status, motor and non-motor symptoms, mobility,…Speech difficulties and dopaminergic neurodegeneration in Parkinson’s Disease
Objective: To evaluate the association between speech difficulties and neurodegeneration of the putaminal dopaminergic system in people with early-stage treated with symptomatic therapy and advanced-stage…COVID-19 associated opsoclonus myoclonus ataxia syndrome
Objective: To present a rare neurological syndrome as a potential parainfectious complication of SARS-CoV-2 infection. Background: Օpsoclonus myoclonus syndrome (OMS) is rare complication of the…Parkinson’s Progression Markers Initiative (PPMI) prioritizes enrollment of individuals from diverse and underrepresented populations
Objective: To describe the goals and Year 1 initiatives of PPMI Diversity, Equity, and Inclusion (DEI) taskforce Background: Clinical trials under-enroll people with Parkinson’s disease…Comparison of cognitive , affective and autonomic functions in parkinson’s disease patients with and without freezing of gait and its correlation with PET/CT
Objective: To study and compare the cognitive, affective and autonomic domains in Parkinson’s disease patients with and without freezing of gait and to correlate with…Altered brain energetics in Parkinson’s Disease: a multimodal neuroimaging study
Objective: To investigate patterns of altered brain energetics in Parkinson’s disease (PD). Background: Alterations in mitochondrial function, related to brain energetics, may play an important…
- « Previous Page
- 1
- …
- 263
- 264
- 265
- 266
- 267
- …
- 1554
- Next Page »